Shaping the Future of Therapeutics

(1006-A) HARNESSING DRUG METABOLITES IN PRECISION MEDICINE: Deeping into antineoplastic’s major metabolites polypharmacology

(1008-A) High-throughput drug-repurposing screening identifies FAK as a potential modulator of the suppressive functions of regulatory T cells.

(1010-A) Miniaturizing drug sensitivity and resistance test for solid tumors on Droplet Microarray

(1013-B) An optimized and validated workflow for developing stable producer cell lines with >99.99% assurance of clonality and high clone recovery

(1054-A) Phytobiotics as antibiotics replacement in broilers poultry production.

(1057-B) Interacting or independent? Systematic testing of drug combinations to identify synergistic and antagonistic drug interactions for melanoma

(1060-A) Therapeutic Potential of the Gut Microbiota in the Management of ulcerative colitis

(1068-A) Modular mini-factories for autonomous & decentralised ATMP production

(1079-B) Characterization and comparison of hypoxia inducing factors on tumor growth and metastasis in 2D and 3D tumor models

(1090-A) Oncotherapeutic and gastro-entero-hepatoprotective potential of bioflavonoids: the example of fustin, isolated from the heartwood of Eurasian smoketree (Cotinus coggygria Scop.), Anacardiaceae

(1099-B) Artificial Intelligence boosts Mode of Action and bioactivity prediction through the integration of Cell Painting images and small molecule structures

(1100-A) Monitoring cell cycle processes critical to cancer development via parallel immunoassays

(1108-A) Breaking Barriers: Expanding Drug Toxicity Modeling through Automated Intestinal Organoids for Enhanced Diversity Representation in the Human Intestinal Epithelium